AMZN
Amazon.com, Inc.
AMZN's fundamentals are mixed: revenue grew 15%, but free cash flow turned negative. Its PE of 22x looks cheaper than it really is, because one-off gains boosted its recent earnings. Analysts expect strong earnings growth.
SRI
Stoneridge, Inc.
There isn't enough reported data to score SRI yet.
AMZN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Weak | |
| Healthy |
AMZN's revenue, profitability and balance sheet are currently healthy, but its cash flow is weak.
SRI Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Under pressure | |
| Strong |
SRI's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
AMZN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 22x | $267 | — |
| Forward | 27x | $267 | — |
| Cheap | 34x | $415 | +55% |
| Fair | 60x | $745 | +179% |
| Expensive | 102x | $1,262 | +372% |
Historical ranges are pointers, not guarantees.
AMZN's PE is in its cheap range at 22x, but its recent earnings include one-off gains. On analysts' estimates for next year's earnings, today's price would be 27x.
SRI PE Valuation
SRI has no meaningful PE right now: it lost money over the past year.
AMZN Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong growth | |
| Growth | |
| Improving | |
| Moderate | |
| Moderate |
Analysts expect earnings and revenue growth for AMZN, with profitability improving.
SRI Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Stable | |
| -- | |
| Limited | |
| -- |
Analysts expect SRI's earnings to decline, with its revenue and profitability holding steady.
AMZN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $9.87 | -20% |
| Q3 2026 | $12.37 | +75% |
| Q2 2026 | $12.43 | +89% |
| Q1 2026 | $8.36 | +36% |
| Q4 2025 | $7.17 | +30% |
| Q3 2025 | $7.08 | +52% |
| Q2 2025 | $6.56 | +57% |
| Q1 2025 | $6.14 | +72% |
| Q4 2024 | $5.53 | +91% |
AMZN has the edge over SRI on earnings quality, reporting a profit while its opponent remains loss making.
SRI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$4.76 | -$3.60 |
| Q2 2026 | -$4.29 | -$3.21 |
| Q1 2026 | -$4.44 | -$3.80 |
| Q4 2025 | -$3.70 | -$3.10 |
| Q3 2025 | -$1.16 | -$0.89 |
| Q2 2025 | -$1.08 | -1643% |
| Q1 2025 | -$0.64 | -$0.50 |
| Q4 2024 | -$0.60 | -$0.41 |
SRI lost $4.76 per share over the past year, a bigger loss than the year before.
AMZN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $201.9B | +12% |
| Q2 2026 | $200.6B | +20% |
| Q1 2026 | $181.5B | +17% |
| Q4 2025 | $213.4B | +14% |
| Q3 2025 | $180.2B | +13% |
| Q2 2025 | $167.7B | +13% |
| Q1 2025 | $155.7B | +8.6% |
| Q4 2024 | $187.8B | +10% |
AMZN has the edge over SRI on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 14% | +4.2 points |
| Q2 2026 | 14% | +2.3 points |
| Q1 2026 | 13% | +1.3 points |
| Q4 2025 | 12% | +0.4 points |
| Q3 2025 | 9.7% | -1.3 points |
| Q2 2025 | 11% | +1.5 points |
| Q1 2025 | 12% | +1.1 points |
| Q4 2024 | 11% | +3.5 points |
AMZN has the edge over SRI on profitability, with a higher operating margin.
SRI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $155.8M | -26% |
| Q2 2026 | $181.4M | -20% |
| Q1 2026 | $160.8M | -26% |
| Q4 2025 | $205.2M | -6% |
| Q3 2025 | $210.3M | -1.7% |
| Q2 2025 | $228M | -3.8% |
| Q1 2025 | $217.9M | -8.9% |
| Q4 2024 | $218.2M | -4.9% |
SRI's revenue has slid since its 2023 peak: $156M last quarter, down 26% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -15% | -14 points |
| Q2 2026 | -0.7% | +0.5 points |
| Q1 2026 | -5.6% | -4.1 points |
| Q4 2025 | -14% | -12 points |
| Q3 2025 | -1.6% | -1.7 points |
| Q2 2025 | -1.1% | -2.6 points |
| Q1 2025 | -1.5% | -1.6 points |
| Q4 2024 | -2% | -4.7 points |
SRI's operating margin was −15% last quarter, down 14 points from the same quarter a year ago, near the bottom of its range since 2019.
AMZN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$34.8B | -8202% |
| Q2 2026 | -$8.8B | -2757% |
| Q1 2026 | -$18.2B | -$10.2B |
| Q4 2025 | $14.9B | -16% |
| Q3 2025 | $430M | -87% |
| Q2 2025 | $332M | -96% |
| Q1 2025 | -$8B | -297% |
| Q4 2024 | $17.8B | -36% |
AMZN's free cash flow was −$46.9B over the past year, against $10.6B the year before.
SRI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$236K | +$2.5M |
| Q2 2026 | $7.7M | +4.5% |
| Q1 2026 | -$12.3M | -356% |
| Q4 2025 | $2.6M | -81% |
| Q3 2025 | -$2.7M | -158% |
| Q2 2025 | $7.4M | +385% |
| Q1 2025 | $4.8M | +46% |
| Q4 2024 | $14M | +1897% |
SRI has the edge over AMZN on cash flow, with more consistent year-over-year improvement.
AMZN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +26M shares |
| 1 year | +0.8% | +84M shares |
| 3 years | +3.5% | +371M shares |
| 5 years | +6.1% | +629M shares |
| Available history | +8.2% | +829M shares |
AMZN has the edge over SRI on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | $3.3B |
SRI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.5% | +143K shares |
| 1 year | +1.9% | +528K shares |
| 3 years | +2.4% | +653K shares |
| 5 years | +4.6% | +1.2M shares |
| Available history | +0.4% | +117K shares |
SRI has 28M diluted shares, up 1.9% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | $5M |
| Q4 2019 | — |
AMZN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.7x | Very low |
| Q2 2026 | 0.3x | Very low |
| Q1 2026 | 0.1x | Very low |
| Q4 2025 | -0.1x | Net Cash |
| Q3 2025 | -0.1x | Net Cash |
| Q2 2025 | -0.0x | Net Cash |
| Q1 2025 | -0.1x | Net Cash |
| Q4 2024 | -0.2x | Net Cash |
AMZN's net debt is less than a year of its operating earnings (EBITDA), after holding more cash than debt a year ago.
SRI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2025 | -2.8x | Net Cash |
| Q2 2025 | 5.2x | High |
| Q1 2025 | 4.3x | High |
| Q4 2024 | -2.1x | Net Cash |
| Q3 2024 | -1.2x | Net Cash |
| Q2 2024 | -0.8x | Net Cash |
| Q1 2024 | -0.9x | Net Cash |
| Q4 2023 | -0.8x | Net Cash |
SRI has more cash than debt.
AMZN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.1 | Neutral |
| Stochastic | 50.0 | Neutral |
AMZN's weekly RSI is 57 (neutral) and its Stochastic is 50 (neutral).
SRI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.1 | Neutral |
| Stochastic | 9.0 | Oversold |
SRI's weekly RSI is 33 (neutral) and its Stochastic is 9 (oversold).
AMZN PE vs Consumer Cyclical Sector
| Metric | AMZN | Sector median | Relative |
|---|---|---|---|
| PE | 22x | 18x | 20% above |
| PE % | 4 | 47 | 43 pts below |
AMZN is trading at 22x earnings, a 20% premium to the Consumer Cyclical sector's median of 18x, though its recent earnings include one-off gains.
SRI PE vs Consumer Cyclical Sector
| Metric | SRI | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 18x | — |
SRI has no meaningful PE right now: it lost money over the past year.
AMZN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $253.6 | 5.5% above |
| 20 week MA | $254.9 | 4.9% above |
| 50 week MA | $242.5 | 10% above |
| 100 week MA | $229.6 | 17% above |
| 200 week MA | $191.4 | 40% above |
AMZN has the edge over SRI on trend strength, trading above more of its moving averages.
SRI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $5.92 | 14% below |
| 20 week MA | $6.68 | 24% below |
| 50 week MA | $6.70 | 24% below |
| 100 week MA | $6.37 | 20% below |
| 200 week MA | $11.5 | 56% below |
SRI is in a downtrend: it's below all five of its weekly moving averages, and 56% below its 200-week average.
AMZN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $93.5 | $158.6 | +70% |
| 2021 | $158.6 | $171.1 | +7.8% |
| 2022 | $171.1 | $85.3 | -50% |
| 2023 | $85.3 | $151.9 | +78% |
| 2024 | $151.9 | $223.8 | +47% |
| 2025 | $223.8 | $232.5 | +3.9% |
| 2026 YTD | $232.5 | $267.4 | +15% |
AMZN has the edge over SRI on returns for 2026, with the stronger performance.
SRI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.7 | $29.6 | -0.1% |
| 2021 | $29.6 | $18.7 | -37% |
| 2022 | $18.7 | $21.3 | +14% |
| 2023 | $21.3 | $19.6 | -8% |
| 2024 | $19.6 | $6.21 | -68% |
| 2025 | $6.21 | $5.69 | -8.4% |
| 2026 YTD | $5.69 | $5.09 | -11% |
SRI has finished three years in a row lower, and it's down 11% so far in 2026.